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Abstract: 
Background/Objectives: Coronary heart disease (CHD) is the number one cause of death in 
women, yet, little is known about women's symptoms. Early symptom recognition of CHD in 
women is essential but most instruments do not assess both prodromal and acute CHD 
symptoms. Our aims were to develop an instrument validly describing women's prodromal and 
acute symptoms of myocardial infarction and to establish reliability of the instrument, the 
McSweeney Acute and Prodromal Myocardial Infarction Symptom Survey (MAPMISS). 
 
Methods: Four studies contributed to the content validity and reliability of this instrument. Two 
qualitative studies provided the list of symptoms that were confirmed in study 3. The resulting 
instrument assesses 37 acute and 33 prodromal symptoms. In study 4, 90 women were retested 7 
to 14 days after their initial survey. We used the kappa statistic to assess agreement across 
administrations. 
 
Results: The women added no new symptoms to the MAPMISS. The average kappa of acute 
symptoms was 0.52 and 0.49 for prodromal. Next we calculated a weighted score. The mean 
acute score for time 1 was 19.4 (SD = 14.43); time 2 was 12.4 (SD = 8.79) with Pearson 
correlation indicating stability (r = .84; P < .01). The mean prodromal score at time 1 was 23.80 
(SD = 24.24); time 2 was 26.79 (SD = 30.52) with a Pearson correlation of r = .72; P < .01. 
 
Conclusions: The tool is comprehensive, has high content validity, and acceptable test-retest 
reliability. Low kappas were related to few women having those symptoms. The symptom scores 
remained stable across administrations. 
myocardial infarction | cardiovascular nursing | nursing | acute heart disease Keywords: 
symptoms | coronary heart disease  
Article: 
Although researchers have focused on cardiovascular disease for the previous 50 years, it 
remains the number one cause of death in men and women. 1 Cardiovascular disease has retained 
this ranking in part because health care professionals do not recognize and subsequently treat 
early warning or prodromal symptoms of coronary heart disease (CHD). 2–4 Prodromal 
symptoms, those symptoms that come and go prior to and change after a myocardial infarction 
(MI), are especially important to identify in women since they experience both higher morbidity 
and disability than men do after a MI. 1 However, only 7% of women identify CHD as women's 
greatest health threat. 5,6 Because most women are unaware of their risk for CHD or do not 
believe their symptoms indicate heart problems, they often ignore prodromal symptoms. 
Likewise, since health care providers learn the symptoms indicative of CHD from studies 
predominately of men whose symptoms often differ from women's symptoms, they have 
difficulty recognizing and treating women's symptoms appropriately. 5–8 
  
Limited studies, primarily with men, have addressed variability of acute MI symptomatology, 
but consensus is growing that women's symptoms of MI vary from men's. 8–14 Although larger 
MI studies included women, they often did not differentiate women's symptoms from men's, 15–
18 or used tools that excluded some important symptoms frequently reported by women, 
according to our preliminary work. 11,12,19–21 Further, no large-scale study has investigated 
both prodromal and acute symptoms in women. Therefore, development of a symptom 
instrument was warranted for earlier diagnosis of CHD in women. 
  
This article discusses 4 studies that contributed to the development and establishment of validity 
and reliability for the symptom portion of an instrument to describe the full range of prodromal 
and acute symptoms: the McSweeney Acute and Prodromal Myocardial Infarction Symptom 
Survey (MAPMISS). This article will describe the content development of the symptom portion 
of the instrument by summarizing 2 qualitative studies (1 and 2). Then, it will describe tool 
development, validity, and reliability by summarizing 2 quantitative studies (3 and 4). The 
University Human Research Advisory Committee approved all studies. 
  
Content Development of the MAPMISS 
   
Study 1: Content Development of Acute Symptoms 
  
This qualitative study explored women's (N = 20) perceptions of causes and symptoms of MI 
with funding from the American Nurses Foundation and Southern Nursing Research Society in 
1993–1994. Women, who had experienced their first MI within the past 24 months, participated 
in individual in-depth interviews about their MI symptoms. Women had no difficulty 
remembering their symptoms since they considered this a life changing experience. The sample 
consisted of white (n = 13; 65%), Hispanic (n = 4; 20%), and black (n = 3; 15%) women. 
Educational levels ranged from less than an eighth grade education (n = 3; 15%) to master's 
degree (n = 4; 20%). Ages ranged from 34 to 77 with a mean age of 61, and 40% had incomes of 
$20,000 or less. Further descriptions of the sample, methods, and findings appear elsewhere. 
22,23 One researcher interviewed each woman twice: the first interview lasted 1.5 to 2 hours 
while the second interview, used to clarify and expand upon content from the first interview, 
averaged 30 minutes. Interviews were tape-recorded, transcribed verbatim, and checked for 
accuracy. The researcher analyzed the narrative using content analysis and constant comparison. 
  
Results indicated that, along with some classic symptoms, women reported many nontraditional 
symptoms both before and during the MI. For instance, one 34-year-old woman experienced 
prodromal symptoms of left arm and shoulder pain and recounted 2 episodes of temporary 
blindness in 1 eye in the month prior to her MI. She associated her blindness episodes with her 
impending MI since she never experienced another episode in the year after her MI. She also 
reported increasingly severe fatigue prior to her MI. In fact, 75% of the participants reported the 
prodromal symptom of unusual fatigue, including 86% of the women of color (n = 7). 4 
Interestingly, 40% of the women initially reported no pain but acute symptoms of indigestion 
and shortness of breath with their MI. Eventually, 30% developed late severe crushing chest pain 
while 25% reported mild-to-no pain throughout the acute MI episode. Women reported 
symptoms of pain in the back under the shoulder blades (30%), in both arms (30%), and in the 
left arm (25%). They also experienced numbness, tingling, or heaviness in the arms. Two women 
had their first migraine headache prior to and did not experience another in the year after the MI. 
Therefore, the majority of women reported experiencing some nontraditional prodromal and 
acute symptoms of MI. 
  
Although this study was designed to focus on acute symptoms, the women reported a surprising 
number and variability of early warning prodromal symptoms that they clearly differentiated 
from their acute symptoms. The definition of prodromal symptoms evolved from their 
descriptions of these early warning symptoms. Results underscored the need to develop an in-
depth list of symptoms women experience before or during MI. 
  
Study 2: Content Development and Validation for Acute and Prodromal Symptoms 
  
This 2-year study, funded by the Arkansas Affiliate of the American Heart Association from 
1996 to 1998, ascertained women's prodromal and acute symptoms associated with their first MI. 
The researcher used in-depth interviews (2 per women) in this descriptive naturalistic study of 40 
women 6 weeks to 1-year post MI and analyzed symptoms using content analysis and constant 
comparison. Because this study focused on describing symptoms before and during the MI event, 
the researcher encouraged the women to describe the precipitating factors, timing, frequency, 
and duration of the symptoms. As in the first study, women had no difficulty recalling their 
symptoms and separating prodromal from acute symptoms. The sample consisted of white (n = 
35; 87.5%), black (n = 4; 10%), and Native American (n = 1; 2.5%) women with 50% having a 
high school education or less. Ages ranged from 27 to 79 years (mean 58.5; SD = 12.53) and 
36% had household incomes of less than $20,000 per year. A complete list and description of 
prodromal and acute symptoms is reported elsewhere. 4,24 The following discussion highlights 
the most frequent prodromal and acute symptoms and compares the most important findings of 
study 2 to those of study 1. 
  
Prodromal Symptoms 
  
Of the 40 women, 37 reported experiencing early warning prodromal symptoms up to 2 years but 
generally about 6 months prior to their MI. They described these symptoms as intermittently 
appearing prior to their MI and as either new symptoms or symptoms they commonly 
experienced prior to the MI but that increased in intensity or frequency prior to the MI. 
Importantly, these symptoms reverted back to previous intensity or frequency or disappeared 
after the MI. The most frequently experienced prodromal symptoms were unusual fatigue (n = 
27), discomfort in the shoulder blade area (n = 21), and chest sensations (n = 20). Eight defined 
the chest sensation as mild discomfort. Fifteen, including all of the Black women, experienced 
shortness of breath, especially with exertion. Eleven women reported frequent indigestion. They 
also noted neurological symptoms of dizziness (n = 11), change in headache intensity/frequency 
or first migraines (n = 11), and vision problems (n = 5). 24 According to the women, the 
neurological/vision problems resolved or resumed at typical frequency/intensity after the MI. 
The frequency of the symptoms varied greatly. Some women identified specific precipitating 
events, such as walking up stairs, while others could not identify any. 
  
Acute Symptoms 
  
During the acute episode, which women defined as the time from onset of unrelenting symptoms 
to time surrounding the diagnosis of the MI, 26 (65%) women experienced some type of chest 
sensation while 16 (40%) complained of sensations in both arms. Fourteen (35%) stated most of 
their discomfort occurred in their back under or between their shoulder blades. Although severe 
chest pain is typically associated with acute MI in men, only 11 women (28%) experienced 
severe pain during their MI. An almost equal number of women, 9 (23%) stated they had no pain 
or only mild discomfort during the acute episode. Further, 3 of the 4 black women reported 
experiencing no pain while the fourth stated she had only mild discomfort. Other frequent acute 
symptoms during the MI were shortness of breath (n = 22), feeling hot and flushed (n = 21), 
unusual fatigue (n = 18), and nausea (n = 16). 24 
  
   
Comparisons Between Study 1 and 2 
  
To compare the results from these 2 studies, individual acute and prodromal symptoms reported 
in each study were examined for similarities and differences along with comparisons of 
percentages of women who reported individual symptoms. Compared with the women in Study 
1, the women in Study 2 experienced similar acute symptoms of back pain beneath or between 
the shoulder blades, generalized chest discomfort, unusual fatigue, nausea, dizziness, sensations 
in both arms, and feeling hot or flushed. Although only 1 black woman in Study 1 reported 
prodromal episodes of temporary blindness, 4 women in Study 2 complained of blurred vision 
prodromally while one woman complained of “not being able to see.” All 4 black women in 
Study 2 reported experiencing shortness of breath and fatigue with their MI. 
  
Women in Study 2 reported the following unique symptoms: (a) losing the taste for cigarettes 
prodromally or during the MI, (b) edema in upper arms, hands, or feet immediately prior to or 
during the acute MI, and (c) prodromal anxiety related to feeling something was “not right.” One 
intriguing finding was that women who reported prodromal symptoms typically experienced 
vague, slowly evolving acute symptoms and delayed seeking treatment for hours, while all 3 of 
the women who experienced only typical acute rapidly evolving symptoms quickly sought 
treatment. Only 1 woman with prodromal symptoms reported rapidly evolving typical acute 
symptoms. No women expressed difficulty remembering their symptoms associated with the life-
threatening event. Studies 1 and 2 were based on small samples; therefore, the researcher decided 
to validate the results with a larger sample of women, using quantitative methodology. Thus, the 
results from Studies 1 and 2 served as the content basis for developing the MAPMISS and also 
provided the definitions for prodromal and acute symptoms. 
  
Development of the MAPMISS 
  
Study 3: Instrument Development: Administration and Content Validity 
  
The Principal Investigator collaborated with a quantitative researcher and statistician to design 
Study 3, funded by an institutional intramural grant, to (a) develop an instrument that 
incorporated the full range of prodromal and acute MI symptoms and the characteristics of the 
symptoms as reported in studies 1 and 2, and (b) determine the feasibility of administering this 
tool via telephone survey. We collected data from 1999–2000. 
  
To convert the qualitative findings to a quantitative measure, we identified all of the acute and 
prodromal symptoms from the first 2 studies. There were 31 general acute symptoms with 2 
components: actual symptoms such as shortness of breath or nausea; and locations, such as pain 
in the back between the shoulder blades. For prodromal symptoms, there were 24 general 
symptoms with the same 2 components as the acute symptoms. 
  
Initially, questions addressing the acute symptoms determined presence or absence and time 
frame (ie, weeks, days, hours, minutes). The questions addressing the prodromal symptoms 
queried the frequency, time frame, and pattern of symptoms. Intensity was initially assessed as 
an overall measurement (no, little, medium, or severe pain) for both acute and prodromal 
symptoms. 
  
Seven content experts, cardiologists, and cardiac nurses established content validity. Five women 
from Study 2 validated the content of the instrument. Neither the experts nor the women added 
any symptoms. At this stage, no further changes were made. 
  
We developed the instrument to be administered by telephone as it would allow for recruitment 
of a large sample from multiple sites and inclusion of women with marginal reading skills. Also, 
data could be collected at a central location, thereby, minimizing the number of data collectors, 
decreasing cost, and increasing reliability. 
  
An expert in survey methods examined the initial draft of the acute and prodromal symptom 
instrument. She suggested numerous revisions for ease in telephone administration. In response, 
we shortened the length of the question stems, reduced the number of choices per question by 
combining choices, and altered the sequence and the timing descriptors of the symptoms. 
  
Next, we pilot tested the instrument with 20 different women who had experienced a MI in the 
previous 12 months. We identified women by medical record review from 2 medical centers in 
Arkansas, then telephoned and asked them to answer and critique the symptom questions. Based 
upon their feedback and our experience of administering the pilot telephone survey, we 
developed the prototype survey instrument. This prototype instrument incorporated numerous 
modifications. For instance, the wording of some items was changed to facilitate clarity and 
some descriptors were added that more clearly described the intensity of the symptoms. The 
sequencing of some questions was revised based on these interviews. Initially, the tool was 
structured in chronological order of symptoms. However, while conducting the interviews, 
women consistently discussed their acute symptoms prior to answering the questions about their 
prodromal symptom intensity and initial occurrence. They used the intensity of the acute 
symptoms to gauge the intensity of the prodromal ones. Also, the women needed to focus on the 
date of the acute event to identify the length of time they had experienced prodromal symptoms 
prior to the acute MI. Therefore, the questions were sequenced to query acute symptoms prior to 
prodromal symptoms. An open-ended question was added to both the prodromal and acute 
sections to allow women to add symptoms that the qualitative studies (1 and 2) may have missed 
because the samples had limited ethnic diversity. The women had no difficulty answering the 
questions using the telephone survey method. 
  
This prototype was tested with 48 women recruited from 4 medical centers in the South who 
were 6 weeks to 1-year post MI. First, a recruiter from each site telephoned women and received 
verbal agreement to release their names to the research team. Then a member of the research 
team called the woman, obtained consent, and conducted the interview by telephone. The 
interviews were recorded on paper copies of the instrument. Data were entered and analyzed 
using SPSS for Windows version 11.0. 
  
Of the 48 women who completed the survey, most were white (n = 42; 87%), while two (4%) 
were black, 3 (6%) were Hispanic, and 1 was Native American (2%). Most (n = 33; 68%) had at 
least a high school education. Ages ranged from 42 to 95 with a mean age of 64, and 33 (64%) 
had annual incomes of less than $30,000. It took them an average of 20 minutes to complete the 
symptom portion of the interview and 40 minutes to finish the entire survey. No subjects 
complained about the length of the interview. 
  
In summary, for acute symptoms, women indicated the presence or absence of symptoms and an 
overall intensity of symptoms. Women had difficulty selecting the timing of onset for their acute 
symptoms (ie, weeks, days, hours, and minutes). Instead, they ordered the sequence of symptoms 
so this was changed on the revised MAPMISS. 
  
For prodromal symptoms the women not only gave presence and absence but also frequency 
without difficulty. Women had difficulty selecting an overall intensity rating because the 
intensity of each prodromal symptom varied. Therefore, an intensity rating was added for each 
prodromal symptom. Women could only describe onset of prodromal symptoms in broad 
categories of week, month, or more than a month prior to MI. The instrument was revised to 
reflect this finding. 
Although the list of symptoms in the MAPMISS captured the majority of responses, it was 
necessary to add numbness of hands (detecting whether in both hands or just one) and arms 
(detecting both, right, or left). Similarly, the general chest pain location was clarified by dividing 
it into 2 questions to more precisely describe location. This resulted in an additional question. 
One question regarding flu-like symptoms was eliminated since no one experienced it. The final 
instrument had 38 acute symptoms (37 plus “other”). (See Table 1 for sample of items). The 
women identified 3 additional prodromal symptoms that were added to the instrument: sleep 
disturbance, difficulty breathing at night, and loss of appetite. The arm, hand, and chest questions 
were split in this section to correspond with the changes in the acute questions. Thus, the final 
instrument had 35 general prodromal (33 plus 2 “other”) symptoms. (See Table 2 for sample of 
items). Five of the women were reinterviewed to test the revised questions. The changes were 
easier for them to answer, and they stated the revised questions more accurately described their 
experiences. This revised version of the MAPMISS was now ready for reliability testing with a 
larger sample of women who had experienced a MI. 
 
With the assistance of a computer programmer, the MAPMISS was converted into an access 
database for direct computer entry of responses. We believed direct data entry would minimize 
missing data, decrease data entry errors, and make telephone administration easier. 
  
Study 4: Reliability Testing of the MAPMISS 
  
This study determined the reliability of the acute and prodromal symptom sections of the 
MAPMISS. The MAPMISS relies completely on recall, which may be influenced by time and 
reflection. Because asking women about their symptoms might cause the women to reflect on 
their symptom experience and alter their responses, it was necessary to confirm test-retest 
reliability of their responses. This study did not address construct validity because in this phase 
of tool development the focus continued to be descriptive with the intent of capturing the 
broadest definitions of symptoms experienced by women with a known MI. 
  
As part of a larger ongoing study funded by the National Institute of Nursing Research 
(McSweeney, September 15, 1999), 90 women from 4 sites in 3 states agreed to participate. We 
conducted this phase of the study from 2001–2002. The procedures for recruitment were similar 
to Study 3. The MAPMISS was administered by telephone. The research assistant conducting the 
telephone interviews defined acute symptoms (unrelenting from initial appearance until 
treatment for MI) to the women prior to asking the acute questions. Similarly, they defined 
prodromal symptoms (intermittent, new onset or change in intensity or frequency prior to MI and 
reverted to former levels or disappeared after the MI) prior to collecting data on prodromal 
symptoms. Since there are multiple symptoms in each category, the research assistants routinely 
repeated the definitions while querying about symptom experiences to facilitate accurate recall. 
Then 7 to 14 days later, the women were recontacted and asked to complete just the symptom 
section of the MAPMISS. This section consisted of questions about women's acute and 
prodromal symptom experiences and took approximately 10 minutes to readminister. The sample 
consisted of white (n = 83; 92%) and black (n = 7; 8%) women. Educational levels ranged from 
less than fourth grade to graduate school with 41% (n = 37) having less than a high school 
education. Ages ranged from 30 to 90 years (mean = 67.6; SD = 11.2) and 53% (n = 48) had 
household incomes of less than $20,000 per year. 
  
During study 4, we added intensity questions for the acute section similar to those for the 
prodromal section. Women could describe the intensity of each acute symptom they experienced, 
and this more accurately reflected their experience rather than an overall intensity rating for their 
acute episode. Women who had completed the survey prior to this change were recontacted and 
completed this revised section. This change allowed us to calculate an overall acute and 
prodromal score for each woman as described below. 
  
To determine stability, agreement coefficients were calculated at the item level across both 
administrations. The kappa statistic for agreement of symptoms was used to correct for chance. 
Kappa was the only statistic that we could use with acute symptoms recorded as either present or 
absent. 25 With the prodromal symptoms, we used both gamma and kappa statistics. Findings 
were similar so only the kappas are reported here since this allows for comparative results for 
acute and prodromal symptoms. Acute and prodromal scores also were calculated for each 
woman. The acute score was the sum of each symptom weighted by its intensity (0 = no 
symptom to 3 = severe). To examine the stability of the acute score, we correlated the scores 
obtained at both times. Next, to determine overall stability of the prodromal symptoms, a 
prodromal score was constructed for each symptom that was the product of its presence/absence, 
intensity, and frequency. All of these scores were summed to create an overall prodromal score. 
The prodromal score from time 1 was correlated with the score from time 2. 
  
Table 3 lists the 37 acute symptoms; no woman reported another symptom. The first 2 columns 
indicate the percent of women reporting each acute symptom at time 1 and time 2. The next 
column gives the raw agreement between these reports. The last column shows kappa, the 
coefficient correcting for chance agreement. Of the 37 acute symptoms, less than 5% of the 
women reported the leg location and numbness in right arm; therefore, their kappas were 
excluded from the overall average since they were likely to be unstable. The average kappa was 
an acceptable 0.52. 
  
The mean acute symptom score was 19.4 (SD = 14.43; median = 17), and ranged from 0 to 70 
for time 1 and 12.4 (SD = 8.79; median = 11.5, range 0–42) for time 2. The score could have 
ranged from 0 (no acute symptoms) to 99 (severe rating for 33 symptoms; symptoms for 
numbness in hands and arms are mutually exclusive). The average number of symptoms at time 
1 was 9.2 (SD = 5.7) with a median of 8 acute symptoms. The reports for time 2 were similar 
with a mean of 9.1 (SD = 5.9) symptoms and a median of 8 acute symptoms. Since the data were 
skewed, we transformed the scores using a logarithmic transformation. However, the results 
were comparable to the untransformed results. For ease of interpretation, the untransformed 
results are reported. Pearson correlation of the acute scores constructed from the 37 acute 
symptoms weighted by their intensity at time 1 and time 2 resulted in a strong relationship (r = 
0.84; P <= 0.01). 
  
No woman added any other prodromal symptoms, resulting in 33 symptoms. Kappa was 
calculated for whether or not they reported the prodromal symptom at time 1 and time 2. Table 4 
provides all of the kappa values. Using the same approach of excluding kappa's when less than 
5% of the sample had the symptom (n = 5 symptoms), the average acceptable kappa was 0.49. 
The mean prodromal score was 23.80 (SD = 24.24; median 15, range 0 to 97) at time 1 and 26.79 
(SD = 30.52; median 16, range 0–175) at time 2. The score could range from 0 (no prodromal 
symptoms) to 522 with all 29 symptoms (the numbness is mutually exclusive) rated as severe (3) 
and occurring at the highest frequency (6). At time 1, the women reported a mean of 6.2 (SD = 
5.2) prodromal symptoms with a median of 5. At time 2, the number was 6.4 (SD = 5.9) and a 
slightly higher median of 6 symptoms. As reported with the acute symptoms, the logarithmic 
transformation yielded comparable results; so the untransformed data results are reported. Using 
Pearson correlation, we examined the correlations of the prodromal score between time 1 and 
time 2. The prodromal score had an acceptable correlation (r = 0.72; P <= .01). 
  
In review, women in Study 4 did not add any acute or prodromal symptoms or locations, 
indicating that the tool is comprehensive. At the item level, no adjustments were made to the list 
of acute symptoms. Leg location rarely occurred, which prevented us from estimating the 
reliability of the symptom. We added intensity questions for each acute symptom similar to those 
in the prodromal section. For the prodromal symptoms, all symptoms were maintained. Most of 
the low kappa's for both acute and prodromal symptoms were related to a small number of 
women having the symptom. Low likelihood may affect the calculation of the coefficient, but is 
insufficient rationale to delete the symptom. 
  
In summary, the MAPMISS is comprehensive and women remain relatively stable in their 
responses at the item level. The summary scores for acute and prodromal remained stable across 
the 2 administrations. Because the scores were positively skewed, a square root transformation 
was done to correct the skewness, but resulted in no changes in the correlation coefficients 
reported above. 
  
Conclusions 
  
In conclusion, the list of symptoms in the MAPMISS was carefully developed from 4 studies. 
The list includes descriptive and location symptoms. We retained the symptom locations and 
expression of the symptom descriptors as verbalized by the subjects in the initial qualitative 
studies. This is an important and appropriate technique to ensure that the quality and meaning of 
qualitative data is maintained while transferring it into a quantitative measure. 26 At this point in 
instrument development, we based item revisions on qualitative assessments by respondents, 
interviewers, and investigators. The symptom descriptors had to be easy to answer and 
accurately reflect the women's experiences. Empirical methods were limited to frequency of 
reported symptoms and incomplete or inconsistent data. Although content experts did not add 
any additional symptoms, women in Study 3 added 3 symptoms. The 90 women in Study 4 did 
not add any further symptoms indicating the tool is comprehensive and has high content validity. 
This shows qualitative methodology (Studies 1 and 2) successfully generates information for tool 
development to study larger samples of women. 
  
Reliability studies indicated some fluctuation at the item level likely due to women reconsidering 
their symptoms after the first interview. However, generally the items had acceptable kappas. 
The kappa coefficients are sensitive to the distribution of responses. Generally, when there are 
few responses, the kappas are not particularly stable. The agreement both from raw agreement 
and from kappa gives us assurance that the reporting of symptoms tends to remain stable. 
Therefore, when considering using this tool in future research that might allow for predicting 
MIs, we feel confident that the symptoms are comprehensive and ones that women remain 
relatively consistent in reporting. 
  
Some symptoms were retained in the MAPMISS even though stability was poor. For example, 
the elaboration of the numbness symptom occurred through the research process, and we assume 
that some women will find it meaningful. The rarely occurring prodromal symptoms were 
retained since they may indicate in future studies the relationship between prodromal and acute 
symptoms. When summarized into acute and prodromal scores, there was high correlation for the 
acute and moderately high correlation for the prodromal scores indicating that these are stable 
scores to use for further research. The prodromal score was the one most likely to shift as a result 
of participating in the first interview. Prodromal symptoms require the women to undertake the 
more difficult task of distinguishing between symptoms prior to the MI from those at the time of 
the MI. This is a task anyone with a MI rarely performs independently (or without prompting). 
  
Research and Practice Implications 
  
With this comprehensive list and the telephone survey methodology, we plan to undertake a 
variety of studies to explore other aspects of validity. We have demonstrated that the tool has 
content validity. However, we have not used it to study predictive validity or concurrent validity 
such as relationship to severity of MI. We are in the position as the number of participants in our 
database grows to determine if acute and prodromal scores differ among women from different 
ethnic backgrounds and with varying comorbidities. Future studies should also include men, as 
prodromal symptoms have not been well studied in any population. 
  
The symptom portion of this instrument may be utilized to assess women's symptoms when they 
present to the Emergency department or to providers' offices with suspected acute coronary 
syndromes. Also, this instrument could be used to retrospectively assess women's individual 
ischemic patterns that occurred prior to and with their MI. Then, discharge teaching could 
incorporate this individualized information to assist women in identifying their specific ischemic 
symptoms and when to appropriately use anti-ischemic medications. Further research must be 
conducted to determine the predictive capability of the prodromal symptoms contained in this 
instrument and to assess how or if risk factors and comorbidities influence symptom 
presentation. If prodromal symptoms are predictive of future CHD events, the prodromal section 
of this instrument will be a useful assessment tool to assist providers in deciding which women 
should be referred for cardiovascular diagnostic evaluation. Early recognition of women's acute 
and prodromal symptoms will facilitate appropriate diagnostic testing and treatment, thus, 
improving outcomes for women with CHD. 
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